News

The facility will manufacture the Ming Che product line of tailor-made lab water purification systems and consumables which will be sold exclusively in China. The products will cater

The European Medicines Agency’s (EMA) acceptance of the marketing authorization application (MAA) of peginesatide has triggered the milestone. Peginesatide, indicated to treat anemia associated with chronic kidney disease

Azul Instant is an all-natural supplement for erectile dysfunction (ED) developed by the comoany as an alternative to prescription drugs. The product carries no side effects, the company

The non-exclusive license agreement covers the delivery of multiple Slonomics-based DNA libraries. As per the agreement, MorphoSys will receive committed annual funding for the delivery of libraries and

TAK-875 is a selective agonist of GPR40, one of the GPCRs that are expressed in pancreatic islet cells. The Phase 2 trial is a randomized double-blind placebo- and

Quintiles and RVC Biofund collaborate to address Russia’s healthcare initiatives in accordance with its Healthcare 2020 Development Program. This will include implementing best practices to support medical science

These agreements will be executed at its Spokane, Washington facility for contract manufacturing of products ranging from liquid to lyophilization presentations, across a variety of patient indications, the

FDA concluded an inspection at the facility in July 2011, to which the company responded detailing the corrective and preventative actions planned to address the Agency’s concerns. In

The CSL Behring rFVIII, called rVIII-SingleChain, is being studied for the treatment of hemophilia A. The open-label, multicenter trial examines the crossover safety, efficacy and pharmacokinetics of recombinant